Indian Pharma and Healthcare H2 FY2024 Half-Annual Update

The Indian pharmaceuticals and healthcare sector is experiencing an increase in activity. India's robust economic growth and the increased health awareness post-pandemic drive more patients and their families to private healthcare service providers. Due to the rising demand, domestic and international investors, as well as an increasing number of private equity funds, are making more investments in the healthcare sector. In the 2024 Union Budget, the government declared a substantial increase in healthcare budgetary allocations. The new budget introduces customs duty exemptions for several high-priced targeted therapies for cancer treatment, thereby increasing their accessibility to Indian patients.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for India. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in India
• Crystallise the forces both driving and restraining this sector in India
• Ascertain India’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in India.
• Build a clear picture of trends, output and consumption for specific sub-sectors